BMS 181184
Alternative Names: BMY 28762; BMY 28801; BMY 28864Latest Information Update: 16 Jan 2008
At a glance
- Originator Bristol-Myers Squibb
 - Class AIDS vaccines; Antifungals; Antivirals; Fungal vaccines
 - Mechanism of Action Cell membrane modulators; HIV envelope protein gp120 inhibitors
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 
Highest Development Phases
- Discontinued HIV infections; Mycoses; Pneumocystis pneumonia
 
Most Recent Events
- 27 Feb 2001 No-Development-Reported for HIV infections treatment in Japan (Parenteral)
 - 27 Feb 2001 No-Development-Reported for HIV infections treatment in United Kingdom (Parenteral)
 - 27 Feb 2001 No-Development-Reported for HIV infections treatment in USA (Parenteral)